Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7122290 + Cibisatamab in Metastatic Colorectal Cancer
NCT04826003Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2021
- Primary completion
- Nov 2024
- Modality
- Fc Fusion Proteins, Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 1, open-label trial of RG7827 in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Roche. Primary endpoints: Dose-Limiting Toxicities at 21 days and Adverse Events at 28 months. Started Jul 2021; status: completed.
02
Drugs
RG7827
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04826003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04826003.